Soegiharto, R. Et Al. 2024. Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study. Allergy: European Journal of Allergy and Clinical Immunology .

Soegiharto, R., Alizadeh Aghdam, M., Sørensen, J., van Lindonk, E., Bulut Demir, F., Mohammad Porras, N., ... Matsuo, Y.(2024). Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study. Allergy: European Journal of Allergy and Clinical Immunology .

Soegiharto, R. Et Al. "Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study," Allergy: European Journal of Allergy and Clinical Immunology , 2024

Soegiharto, R. Et Al. "Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study." Allergy: European Journal of Allergy and Clinical Immunology , 2024

Soegiharto, R. Et Al. (2024) . "Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study." Allergy: European Journal of Allergy and Clinical Immunology .

@article{article, author={R. Soegiharto Et Al. }, title={Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study}, journal={Allergy: European Journal of Allergy and Clinical Immunology}, year=2024}